NCT04337177 2025-09-23Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLCPhase 1 Recruiting20 enrolled
NCT02085148 2024-04-22A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard TherapyBayerPhase 1 Completed62 enrolled